Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Rev. bras. cir. cardiovasc ; 32(2): 96-103, Mar.-Apr. 2017. tab
Article in English | LILACS | ID: biblio-843481

ABSTRACT

Abstract INTRODUCTION: The mortality due to cardiogenic shock complicating acute myocardial infarction (AMI) is high even in patients with early revascularization. Infusion of low dose recombinant human brain natriuretic peptide (rhBNP) at the time of AMI is well tolerated and could improve cardiac function. OBJECTIVE: The objective of this study was to evaluate the hemodynamic effects of rhBNP in AMI patients revascularized by emergency percutaneous coronary intervention (PCI) who developed cardiogenic shock. METHODS: A total of 48 patients with acute ST segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock and whose hemodynamic status was improved following emergency PCI were enrolled. Patients were randomly assigned to rhBNP (n=25) and control (n=23) groups. In addition to standard therapy, study group individuals received rhBNP by continuous infusion at 0.005 µg kg−1 min−1 for 72 hours. RESULTS: Baseline characteristics, medications, and peak of cardiac troponin I (cTnI) were similar between both groups. rhBNP treatment resulted in consistently improved pulmonary capillary wedge pressure (PCWP) compared to the control group. Respectively, 7 and 9 patients died in experimental and control groups. No drug-related serious adverse events occurred in either group. CONCLUSION: When added to standard care in stable patients with cardiogenic shock complicating anterior STEMI, low dose rhBNP improves PCWP and is well tolerated.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Natriuretic Peptide, Brain/administration & dosage , Anterior Wall Myocardial Infarction/drug therapy , Percutaneous Coronary Intervention/mortality , ST Elevation Myocardial Infarction/drug therapy , Shock, Cardiogenic/etiology , Blood Pressure/drug effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Pulmonary Wedge Pressure/drug effects , Analysis of Variance , Natriuretic Peptide, Brain/therapeutic use , Natriuretic Peptide, Brain/pharmacology , Anterior Wall Myocardial Infarction/complications , Anterior Wall Myocardial Infarction/mortality , ST Elevation Myocardial Infarction/complications , ST Elevation Myocardial Infarction/mortality , Heart Rate/drug effects , Intra-Aortic Balloon Pumping/methods
2.
Rev. chil. obes ; 6(1): 5-15, 2001. tab
Article in Spanish | LILACS | ID: lil-314845

ABSTRACT

In the last decade, specially after the discovery of leptin, several neuropeptides that regulate energy intake and expenditure have been described in animal models. This has partially unvelied the underlying mechanisms that regulate body composition and weight and therefore a promise of a more effective treatment of obesity and its comorbidities is ad portas


Subject(s)
Humans , Diabetes Mellitus, Type 2 , Insulin Resistance , Obesity , Appetite Regulation/genetics , Fatty Acids/genetics , Acylation , Diabetes Mellitus, Type 2 , Dopamine , Atrial Natriuretic Factor/pharmacology , Hypertension/etiology , Leptin , Lipolysis , Molecular Biology , Mutation/genetics , Neuropeptides/pharmacology , Obesity , Natriuretic Peptide, Brain/pharmacology , Natriuretic Peptide, C-Type/pharmacology , Peroxisome Proliferators , Protein Tyrosine Phosphatases/pharmacology , Receptors, Adrenergic, beta/genetics , Uncoupling Agents
SELECTION OF CITATIONS
SEARCH DETAIL